The capability of an early prognosis for the treatment of Chronic Hepatitis C (CH-C) patients with genotype 1b and high viral loads with Pegylated Interferon-α2b plus Ribavirin was evaluated by the levels of serum HCV core antigens. Serum samples were drawn before the treatment, 3 days or 1, 2, 4, and 12 weeks after the treatment. Out of 45 cases with CH-C, 36 cases (80%) and 9 cases (20%) were early virological response (EVR) and non-early virological response (NEVR), respectvery.
The serum levels of core antigen in EVR were significantly lower than those in NEVR from the third day to the 12
th week after the treatment. The levels of core antigen less than 1000fmol/L in the second week could predict a better prognosis in the 12
th week. The measurement of serum HCV core antigen was useful for the early prognosis of the treatment in CH-C patients with genotype 1b and high viral loads with Pegylated Interferon-α2b plus Ribavirin.
View full abstract